The digital health platform MedWatcher has further bridged the gap between patients and the scientific community by entering into an important partnership with the European Organization for Research and Treatment of Cancer (EORTC). This collaboration aims to promote the collection and analysis of Patient-Reported Outcomes (PRO) to improve cancer research and treatment. Through the collaboration with EORTC, MedWatcher offers cancer patients access to standardized quality of life questionnaires that can be used outside of clinical trials in the "real world". The platform has already published the computerized adaptive testing version of the QLQ-C30 quality of life questionnaire and plans to publish disease-specific questionnaires for different cancer types to provide a comprehensive picture of patient experience and care.
MedWatcher is more than just a platform for patients to get information about their health; it is a valuable resource for life science companies and academic institutions to collect real-world data for their research. The data collected is not only useful for assessing quality of life, but also provides insights into the efficacy and tolerability of therapies from the patient's perspective. The partnership with EORTC underscores MedWatcher's commitment to improving the understanding and treatment of cancer by fostering collaboration between patients, healthcare providers and the scientific community. The content on the platform comes from various renowned partners, including "Apotheken Umschau", medical professionals, research institutions and manufacturers, making the platform a trusted source of health information.
